HOME Research Insight Market Leader - In Vivo Toxicology Market



Market Leader - In Vivo Toxicology Market


The in vivo toxicology market is projected to reach USD 6.14 Billion by 2022 from USD 4.40 Billion in 2017, at a CAGR of 6.9%. Factors such as increasing pharmaceutical R&D activities, mandatory government regulations for animal testing, innovations in animal models, and the development of exclusive in vivo toxicology tests are driving the growth of this market.

In this report, the market is segmented by product, testing type, toxicity endpoint, testing facility, and region.

On the basis of product, the in vivo toxicology market is segmented into consumables and instruments. The consumables segment is further divided into reagents & kits and animal models (including mice model, rat model, and other animal models). The instruments segment is expected to grow at the highest CAGR during the forecast period. This is mainly attributed to the increasing research focus on neurological disorders where physiological equipment is used and the increasing research capabilities focused on biological samples such as blood and urine. In the animal models subsegment, mice models segment is expected to grow at the highest CAGR during the forecast period owing to its similarities with human genomes, advantages over other animal models, and innovation in the transgenic models.

Based on testing type, the in vivo toxicology market is segmented into chronic, sub-chronic, sub-acute, and acute toxicology testing. The sub-acute toxicity testing segment is expected to register the highest CAGR of during the forecast period. Growth in this market is attributed to the increasing neurological and anti-viral drug research, which require toxicity studies of more than two weeks.

Based on toxicity endpoint, the in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental and reproductive toxicity (DART), and other toxicity endpoints. The immunotoxicity segment is expected to register the highest CAGR during the forecast period. The rising demand for the development of biologics and biosimilars is driving the growth of the immunotoxicity segment.

On the basis of testing facility, the global in vivo toxicology market is segmented into outsourced testing facilities and in-house testing facilities. The outsourced testing facilities segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment is mainly attributed to the increasing R&D investments and cost-saving strategies of pharmaceutical, biopharmaceutical, and medical devices companies, which in turn results in increasing outsourcing of services to CROs.

Geographically, China is expected to grow at the highest CAGR during the forecast period. Factors such as rising number of CROs that offer cost-effective in vivo toxicology services, growing pharmaceuticals industry, and government initiatives for the development of research in the country are driving the growth of the in vivo toxicology market in China.  

Related Reports:

In Vivo Toxicology Market by Product (Instruments, Consumables (Animal models, Reagents & Kits)), Testing type (Chronic, Sub-chronic), Toxicity Endpoints (Immunotoxicity, Systemic, DART), Testing Facility (Outsourced, In-house) - Global Forecast to 2022

Contact:
Mr. Rohan
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports